Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma

被引:47
作者
Even-Sapir, Einat [3 ,4 ]
Israel, Ora [1 ,2 ]
机构
[1] Technion Israel Inst Technol, Dept Nucl Med, Rambam Med Ctr, IL-35254 Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, IL-35254 Haifa, Israel
[3] Tel Aviv Univ, Dept Nucl Med, Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
non-Hodgkin's lymphoma; Hodgkin's disease; gallium-67; SPET; FDG;
D O I
10.1007/s00259-003-1164-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Until recently, gallium-67 scintigraphy (GS) has been the best available functional imaging modality for evaluating patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). The diagnostic accuracy of GS in detecting lymphoma is based on optimisation of the imaging protocol, knowledge of potential physiological and benign sites of Ga-67 uptake, and the Ga avidity characteristics of the individual lymphoma. As Ga-67 is a tumour viability agent, the role of GS is primarily at follow-up. A residual mass persisting on CT after treatment poses a common clinical dilemma: it may indicate the presence of viable lymphoma, which requires further treatment, or it can be benign, consisting of only fibrotic and necrotic tissues. GS can successfully differentiate between these conditions. Routine follow-up with GS may allow early diagnosis of recurrence and early institution of treatment. Reversion of a positive GS to a negative test, and the rapidity with which this occurs has a high predictive value for the outcome of the individual patient. Lymphoma showing a normal GS early during treatment has a better prognosis than lymphoma with persistence of pathological findings. Other tumour-seeking single-photon emitting agents, such as thallium-201, technetium-99m methoxyisobutylisonitrile and indium-111 octreotide, have been investigated in lymphoma, primarily as an alternative to GS in specific clinical settings, but are of limited value. The role of radioimmunoscintigraphy is gaining importance in conjunction with radioimmunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) imaging of lymphoma using either dedicated or camera-based PET systems is gradually replacing GS for assessment of lymphoma. FDG overcomes some of the limitations of GS while sharing its tumour viability characteristics. The extensive clinical knowledge and experience accumulated over three decades with GS in lymphoma provides a solid background as well as a model for the assessment of new functional imaging techniques.
引用
收藏
页码:S65 / S81
页数:17
相关论文
共 176 条
  • [1] CLINICAL-EXPERIENCE WITH TC-99M MIBI IMAGING IN PATIENTS WITH MALIGNANT-TUMORS - PRELIMINARY-RESULTS AND COMPARISON WITH TL-201
    AKTOLUN, C
    BAYHAN, H
    KIR, M
    [J]. CLINICAL NUCLEAR MEDICINE, 1992, 17 (03) : 171 - 176
  • [2] HIGH-DOSE GALLIUM IMAGING IN LYMPHOMA
    ANDERSON, KC
    LEONARD, RCF
    CANELLOS, GP
    SKARIN, AT
    KAPLAN, WD
    [J]. AMERICAN JOURNAL OF MEDICINE, 1983, 75 (02) : 327 - 331
  • [3] BIODISTRIBUTIONS OF TL-201 IN TUMOR-BEARING ANIMALS AND INFLAMMATORY LESION INDUCED ANIMALS
    ANDO, A
    ANDO, I
    KATAYAMA, M
    SANADA, S
    HIRAKI, T
    MORI, H
    TONAMI, N
    HISADA, K
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1987, 12 (11): : 567 - 572
  • [4] ANDREWS GA, 1978, J NUCL MED, V19, P1013
  • [5] TUMOR SCANNING WITH GALLIUM-67
    ANDREWS, GA
    EDWARDS, CL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1975, 233 (10): : 1100 - 1103
  • [6] ANKERLUGTENBURG PJ, 1996, BRIT J HAEMATOL, V93, P96
  • [7] ANKERLUTKENBURG PJ, 1996, METABOLISM S1, V45, P96
  • [8] CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS
    ARMITAGE, JO
    WEISENBURGER, DD
    HUTCHINS, M
    MORAVEC, DF
    DOWLING, M
    SORENSEN, S
    MAILLIARD, J
    OKERBLOOM, J
    JOHNSON, PS
    HOWE, D
    BASCOM, GK
    CASEY, J
    LINDER, J
    PURTILO, DT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) : 160 - 164
  • [9] The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment
    Bar-Shalom, R
    Mor, M
    Yefremov, N
    Goldsmith, SJ
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2001, 31 (03) : 177 - 190
  • [10] PET imaging in oncology
    Bar-Shalom, R
    Valdivia, AY
    Blaufox, MD
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2000, 30 (03) : 150 - 185